Unknown OBSERVATIONAL NCT03090815

Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma

Sponsor: Feinstein Institute for Medical Research

Conditions Adenocarcinoma of Lung (Disorder)

Interventions Sequencing of ctDNA in plasma

Updated 7 times since 2017 Last updated: Mar 20, 2017 Started: Feb 29, 2016 Primary completion: Dec 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03090815, this observational or N/A phase trial focuses on Adenocarcinoma of Lung (Disorder) and remains ongoing. Sponsored by Feinstein Institute for Medical Research, it has been updated 7 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Apr 2019 — Jan 2021 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jun 2018 — Apr 2019 [monthly]

Recruiting

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Recruiting

Phase: NA → None
May 2017 — Apr 2018 [monthly]

Recruiting NA

First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Feinstein Institute for Medical Research
The University of Hong Kong

Data source: The University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hong Kong, Hong Kong